Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

BRD4 degradation blocks expression of MYC and multiple forms of stem cell resistance in Ph+ chronic myeloid leukemia

B. Peter, G. Eisenwort, I. Sadovnik, K. Bauer, M. Willmann, T. Rülicke, D. Berger, G. Stefanzl, G. Greiner, G. Hoermann, A. Keller, D. Wolf, M. Čulen, GE. Winter, T. Hoffmann, AI. Schiefer, WR. Sperr, J. Zuber, J. Mayer, P. Valent

. 2022 ; 97 (9) : 1215-1225. [pub] 20220718

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc22024501

Grantová podpora
F4701-B20 Austrian Science Fund
F4704-B20 Austrian Science Fund
F4710-B20 Austrian Science Fund
P30625-B28 Austrian Science Fund
Research Grant Celgene

In most patients with chronic myeloid leukemia (CML) clonal cells can be kept under control by BCR::ABL1 tyrosine kinase inhibitors (TKI). However, overt resistance or intolerance against these TKI may occur. We identified the epigenetic reader BRD4 and its downstream-effector MYC as growth regulators and therapeutic targets in CML cells. BRD4 and MYC were found to be expressed in primary CML cells, CD34+ /CD38- leukemic stem cells (LSC), and in the CML cell lines KU812, K562, KCL22, and KCL22T315I . The BRD4-targeting drug JQ1 was found to suppress proliferation in KU812 cells and primary leukemic cells in the majority of patients with chronic phase CML. In the blast phase of CML, JQ1 was less effective. However, the BRD4 degrader dBET6 was found to block proliferation and/or survival of primary CML cells in all patients tested, including blast phase CML and CML cells exhibiting the T315I variant of BCR::ABL1. Moreover, dBET6 was found to block MYC expression and to synergize with BCR::ABL1 TKI in inhibiting the proliferation in the JQ1-resistant cell line K562. Furthermore, BRD4 degradation was found to overcome osteoblast-induced TKI resistance of CML LSC in a co-culture system and to block interferon-gamma-induced upregulation of the checkpoint antigen PD-L1 in LSC. Finally, dBET6 was found to suppress the in vitro survival of CML LSC and their engraftment in NSG mice. Together, targeting of BRD4 and MYC through BET degradation sensitizes CML cells against BCR::ABL1 TKI and is a potent approach to overcome multiple forms of drug resistance in CML LSC.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22024501
003      
CZ-PrNML
005      
20221031100935.0
007      
ta
008      
221017s2022 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1002/ajh.26650 $2 doi
035    __
$a (PubMed)35794848
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Peter, Barbara $u Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Vienna, Austria $u Department of Internal Medicine I, Division of Hematology & Hemostaseology, Medical University of Vienna, Vienna, Austria $1 https://orcid.org/https://orcid.org/0000000157015412
245    10
$a BRD4 degradation blocks expression of MYC and multiple forms of stem cell resistance in Ph+ chronic myeloid leukemia / $c B. Peter, G. Eisenwort, I. Sadovnik, K. Bauer, M. Willmann, T. Rülicke, D. Berger, G. Stefanzl, G. Greiner, G. Hoermann, A. Keller, D. Wolf, M. Čulen, GE. Winter, T. Hoffmann, AI. Schiefer, WR. Sperr, J. Zuber, J. Mayer, P. Valent
520    9_
$a In most patients with chronic myeloid leukemia (CML) clonal cells can be kept under control by BCR::ABL1 tyrosine kinase inhibitors (TKI). However, overt resistance or intolerance against these TKI may occur. We identified the epigenetic reader BRD4 and its downstream-effector MYC as growth regulators and therapeutic targets in CML cells. BRD4 and MYC were found to be expressed in primary CML cells, CD34+ /CD38- leukemic stem cells (LSC), and in the CML cell lines KU812, K562, KCL22, and KCL22T315I . The BRD4-targeting drug JQ1 was found to suppress proliferation in KU812 cells and primary leukemic cells in the majority of patients with chronic phase CML. In the blast phase of CML, JQ1 was less effective. However, the BRD4 degrader dBET6 was found to block proliferation and/or survival of primary CML cells in all patients tested, including blast phase CML and CML cells exhibiting the T315I variant of BCR::ABL1. Moreover, dBET6 was found to block MYC expression and to synergize with BCR::ABL1 TKI in inhibiting the proliferation in the JQ1-resistant cell line K562. Furthermore, BRD4 degradation was found to overcome osteoblast-induced TKI resistance of CML LSC in a co-culture system and to block interferon-gamma-induced upregulation of the checkpoint antigen PD-L1 in LSC. Finally, dBET6 was found to suppress the in vitro survival of CML LSC and their engraftment in NSG mice. Together, targeting of BRD4 and MYC through BET degradation sensitizes CML cells against BCR::ABL1 TKI and is a potent approach to overcome multiple forms of drug resistance in CML LSC.
650    _2
$a zvířata $7 D000818
650    _2
$a blastická krize $x farmakoterapie $7 D001752
650    _2
$a proteiny buněčného cyklu $7 D018797
650    _2
$a nádorové buněčné linie $7 D045744
650    _2
$a chemorezistence $7 D019008
650    _2
$a bcr-abl fúzní proteiny $7 D016044
650    _2
$a lidé $7 D006801
650    12
$a chronická myeloidní leukemie $x farmakoterapie $x genetika $x metabolismus $7 D015464
650    _2
$a myši $7 D051379
650    12
$a jaderné proteiny $x genetika $7 D009687
650    _2
$a inhibitory proteinkinas $x farmakologie $x terapeutické užití $7 D047428
650    _2
$a protoonkogenní proteiny c-myc $7 D016271
650    _2
$a kmenové buňky $7 D013234
650    _2
$a transkripční faktory $x genetika $7 D014157
655    _2
$a časopisecké články $7 D016428
700    1_
$a Eisenwort, Gregor $u Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Vienna, Austria $u Department of Internal Medicine I, Division of Hematology & Hemostaseology, Medical University of Vienna, Vienna, Austria $1 https://orcid.org/https://orcid.org/0000000327354645
700    1_
$a Sadovnik, Irina $u Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Vienna, Austria $u Department of Internal Medicine I, Division of Hematology & Hemostaseology, Medical University of Vienna, Vienna, Austria $1 https://orcid.org/https://orcid.org/0000000154185942
700    1_
$a Bauer, Karin $u Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Vienna, Austria $u Department of Internal Medicine I, Division of Hematology & Hemostaseology, Medical University of Vienna, Vienna, Austria
700    1_
$a Willmann, Michael $u Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Vienna, Austria $u Department for Companion Animals and Horses, University Clinic for Small Animals, Internal Medicine Small Animals, University of Veterinary Medicine Vienna, Vienna, Austria
700    1_
$a Rülicke, Thomas $u Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Vienna, Austria $u Institute of Laboratory Animal Science, University of Veterinary Medicine Vienna, Vienna, Austria $1 https://orcid.org/https://orcid.org/0000000221219496
700    1_
$a Berger, Daniela $u Department of Internal Medicine I, Division of Hematology & Hemostaseology, Medical University of Vienna, Vienna, Austria
700    1_
$a Stefanzl, Gabriele $u Department of Internal Medicine I, Division of Hematology & Hemostaseology, Medical University of Vienna, Vienna, Austria
700    1_
$a Greiner, Georg $u Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Vienna, Austria $u Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria $1 https://orcid.org/https://orcid.org/0000000209174117
700    1_
$a Hoermann, Gregor $u Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Vienna, Austria $u Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria $u MLL Munich Leukemia Laboratory, Munich, Germany $1 https://orcid.org/https://orcid.org/0000000273744380
700    1_
$a Keller, Alexandra $u Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Vienna, Austria $u Department of Internal Medicine I, Division of Hematology & Hemostaseology, Medical University of Vienna, Vienna, Austria
700    1_
$a Wolf, Dominik $u Department of Hematology and Oncology, Innsbruck Medical University, Innsbruck, Austria $u Department of Hematology, Oncology and Rheumatology, Center of Integrated Oncology Cologne Bonn, University Hospital of Bonn, Bonn, Germany
700    1_
$a Čulen, Martin $u Department of Internal Medicine, Hematology and Oncology, Faculty of Medicine, Masaryk University, Brno, Czech Republic $u Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, Brno, Czech Republic $1 https://orcid.org/https://orcid.org/0000000287105352
700    1_
$a Winter, Georg E $u CeMM-Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria $1 https://orcid.org/https://orcid.org/0000000166061437
700    1_
$a Hoffmann, Thomas $u Research Institute of Molecular Pathology (IMP), Vienna BioCenter (VBC), Vienna, Austria
700    1_
$a Schiefer, Ana-Iris $u Department of Pathology, Medical University of Vienna, Vienna, Austria $1 https://orcid.org/https://orcid.org/0000000335558672
700    1_
$a Sperr, Wolfgang R $u Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Vienna, Austria $u Department of Internal Medicine I, Division of Hematology & Hemostaseology, Medical University of Vienna, Vienna, Austria $1 https://orcid.org/https://orcid.org/0000000332888027
700    1_
$a Zuber, Johannes $u Research Institute of Molecular Pathology (IMP), Vienna BioCenter (VBC), Vienna, Austria $u Medical University of Vienna, Vienna BioCenter (VBC), Vienna, Austria $1 https://orcid.org/https://orcid.org/0000000188106835
700    1_
$a Mayer, Jiří $u Department of Internal Medicine, Hematology and Oncology, Faculty of Medicine, Masaryk University, Brno, Czech Republic $u Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, Brno, Czech Republic
700    1_
$a Valent, Peter $u Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Vienna, Austria $u Department of Internal Medicine I, Division of Hematology & Hemostaseology, Medical University of Vienna, Vienna, Austria $1 https://orcid.org/https://orcid.org/0000000304565095
773    0_
$w MED00000251 $t American journal of hematology $x 1096-8652 $g Roč. 97, č. 9 (2022), s. 1215-1225
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35794848 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20221017 $b ABA008
991    __
$a 20221031100931 $b ABA008
999    __
$a ok $b bmc $g 1854296 $s 1175791
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 97 $c 9 $d 1215-1225 $e 20220718 $i 1096-8652 $m American journal of hematology $n Am J Hematol $x MED00000251
GRA    __
$a F4701-B20 $p Austrian Science Fund
GRA    __
$a F4704-B20 $p Austrian Science Fund
GRA    __
$a F4710-B20 $p Austrian Science Fund
GRA    __
$a P30625-B28 $p Austrian Science Fund
GRA    __
$a Research Grant $p Celgene
LZP    __
$a Pubmed-20221017

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace